279 related articles for article (PubMed ID: 30504315)
1. Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation.
Hamilton BK
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):228-235. PubMed ID: 30504315
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Will post-transplantation cell therapies for pediatric patients become standard of care?
Lankester AC; Locatelli F; Bader P; Rettinger E; Egeler M; Katewa S; Pulsipher MA; Nierkens S; Schultz K; Handgretinger R; Grupp SA; Boelens JJ; Bollard CM;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):402-11. PubMed ID: 25064748
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
6. Oral graft-versus-host disease.
Kuten-Shorrer M; Woo SB; Treister NS
Dent Clin North Am; 2014 Apr; 58(2):351-68. PubMed ID: 24655527
[TBL] [Abstract][Full Text] [Related]
7. Acral verruca-like presentation of chronic graft-vs.-host disease.
Park JH; Lester L; Kim J; Kwong BY
J Cutan Pathol; 2016 Mar; 43(3):236-41. PubMed ID: 26449730
[TBL] [Abstract][Full Text] [Related]
8. New treatment options for the management of acute graft-versus-host disease.
Chen YB
Clin Adv Hematol Oncol; 2019 Sep; 17(9):482-485. PubMed ID: 31549967
[No Abstract] [Full Text] [Related]
9. Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.
Cuthbertson P; Geraghty NJ; Adhikary SR; Bird KM; Fuller SJ; Watson D; Sluyter R
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361109
[TBL] [Abstract][Full Text] [Related]
10. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
11. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
14. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
15. Chinese Medicine Treatment on Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Wu XL; Zhuang HF; Zhao YN; Yu XL; Dai TY; Gao RL
Chin J Integr Med; 2020 May; 26(5):324-329. PubMed ID: 32350801
[TBL] [Abstract][Full Text] [Related]
16. Increased bacterial infections after transfusion of leukoreduced non-irradiated blood products in recipients of allogeneic stem cell transplants after reduced-intensity conditioning.
Jaime-Pérez JC; Villarreal-Villarreal CD; Salazar-Riojas R; Méndez-Ramírez N; Vázquez-Garza E; Gómez-Almaguer D
Biol Blood Marrow Transplant; 2015 Mar; 21(3):526-30. PubMed ID: 25498924
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report.
Gigli F; Gardellini A; Babic A; Liptrott SJ; Castagna L; Martinelli G; Laszlo D
Transfus Apher Sci; 2013 Oct; 49(2):205-7. PubMed ID: 23491865
[TBL] [Abstract][Full Text] [Related]
18. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
19. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.
Harris AC; Young R; Devine S; Hogan WJ; Ayuk F; Bunworasate U; Chanswangphuwana C; Efebera YA; Holler E; Litzow M; Ordemann R; Qayed M; Renteria AS; Reshef R; Wölfl M; Chen YB; Goldstein S; Jagasia M; Locatelli F; Mielke S; Porter D; Schechter T; Shekhovtsova Z; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 Jan; 22(1):4-10. PubMed ID: 26386318
[TBL] [Abstract][Full Text] [Related]
20. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
